A Liftstream analysis reportedly shows that the average board of directors in the biotechnology sphere is roughly 90 percent male and more than half of all boardrooms have no women at all. Based on data from 1,150 life sciences companies in the United States and Europe, the study found better diversity on the boards of companies with 1,000 or more employees, but women still accounted for just 19 percent of such boards, with only 15 percent in functional leadership positions. In those companies with fewer than 1,000 employees, where the hiring process is unstructured and relies heavily on personal networks, the representation of women on corporate boards was minimal, with women holding 10 percent of available board seats and just 4 percent of board chairs. Because board membership often begins in executive suites, the numbers could improve with increasing numbers of women in biotech C-suites. Still, those men concerned about gender equality understand that they must recognize that bias exists and be involved in the discussion to effectuate any change. See FierceBiotech, October 23, 2014.